Advertisement

Topics

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

2018-02-27 21:08:13 | BioPortfolio

Published on BioPortfolio: 2018-02-27T21:08:13-0500

Clinical Trials [915 Associated Clinical Trials listed on BioPortfolio]

Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

Researchers want to find out if giving the drug Apremilast in combination with Clobetasol spray can help people clear their moderate to severe plaque psoriasis quicker than if Apremilast i...

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

The purpose of this study is to test if the study drug apremilast is safe, if it helps improve psoriasis, and how subjects tolerate it.

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate p...

Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast. This data will be complemented by immunohistochemical...

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.

PubMed Articles [782 Associated PubMed Articles listed on BioPortfolio]

Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.

Response to etanercept therapy in patients who have failed apremilast therapy has not been well characterized.

Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.

Apremilast has demonstrated a favourable safety profile for the treatment of psoriasis based on its pivotal randomized controlled trials (RCTs), ESTEEM 1 and 2. One-year safety data suggested that apr...

Antistreptococcal interventions for guttate and chronic plaque psoriasis.

Psoriasis is a chronic skin disease that affects approximately two per cent of the general population. Plaque psoriasis is the most common form: it usually appears as raised, red patches of inflamed s...

Calcipotriol plus betamethasone dipropionate aerosol foam versus apremilast, methotrexate, acitretin, or fumaric acid esters for the treatment of plaque psoriasis: A matching-adjusted indirect comparison.

Plaque psoriasis has significant impact on patients' quality of life. Topical therapy is considered the treatment mainstay for mild-to-moderate disease according to guidelines. Calcipotriol/betamethas...

Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.

Ocular comorbidity has been reported in 10-15% of patients with plaque psoriasis. This paper reports successful treatment with secukinumab of a patient with plaque psoriasis and dry eye syndrome. Both...

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Endovascular procedure in which atheromatous plaque is excised by a cutting or rotating catheter. It differs from balloon and laser angioplasty procedures which enlarge vessels by dilation but frequently do not remove much plaque. If the plaque is removed by surgical excision under general anesthesia rather than by an endovascular procedure through a catheter, it is called ENDARTERECTOMY.

The term applied to a group of relatively uncommon inflammatory, maculopapular, scaly eruptions of unknown etiology and resistant to conventional treatment. Eruptions are both psoriatic and lichenoid in appearance, but the diseases are distinct from psoriasis, lichen planus, or other recognized dermatoses. Proposed nomenclature divides parapsoriasis into two distinct subgroups, PITYRIASIS LICHENOIDES and parapsoriasis en plaques (small- and large-plaque parapsoriasis).

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

An index which scores the degree of dental plaque accumulation.

More From BioPortfolio on "Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial